The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mesenchymal stromal cell exosome–enhanced regulatory T-cell production through an antigen-presenting cell–mediated pathway
Open accessAbstract
Background aims The immunomodulatory property of mesenchymal stromal cell (MSC) exosomes is well documented. On the basis of our previous report that MSC exosomes increased regulatory T-cell (Treg) production in mice with allogenic skin graft but not in ungrafted mice, we hypothesize that an activated immune system is key to exosome-mediated Treg production. Methods To test our hypothesis, MSC exosomes were incubated with mouse spleen CD4 + T cells that were activated with either anti-CD3/CD28 mAbs or allogenic antigen-presenting cell (APC)-enriched spleen CD11c + cells to determine whether production of mouse CD4 + CD25 + T cells or CD4 + CD25 + Foxp3 + Tregs could be induced. MSC exosomes were also administered to the lethal chimeric human-SCID mouse model of graft-versus-host disease (GVHD) in which human peripheral blood mononuclear cells were infused into irradiated NSG mice to induce GVHD. Results We report here that MSC exosome–induced production of CD4 + CD25 + T cells or CD4 + CD25 + Foxp3 + Tregs from CD4 + T cells activated by allogeneic APC-enriched CD11C + cells but not those activated by anti-CD3/CD28 mAbs. This induction was exosome- and APC dose–dependent. In the mouse GVHD model in which GVHD was induced by transplanted human APC-stimulated human anti-mouse CD4 + T cell effectors, MSC exosome alleviated GVHD symptoms and increased survival. Surviving exosome-treated mice had a significantly higher level of human CD4 + CD25 + CD127 low/– Tregs than surviving mice treated with Etanercept, a tumor necrosis factor inhibitor. Conclusions MSC exosome enhanced Treg production in vitro and in vivo through an APC-mediated pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease
Lai, R. C., Chen, T. S., & Lim, S. K. (2011) · Regenerative Medicine · doi:10.2217/rme.11.35 · Cited by 553
Self-citation
Cited by
Zhang, S., Teo, K. Y. W., Chuah, S. J., Lai, R. C., Lim, S. K., & Toh, W. S. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.02.006 · Cited by 572
Self-citationStem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders
Riazifar, M., Mohammadi, M. R., Pone, E. J., Yeri, A., Lässer, C., Segaliny, A. I., McIntyre, L. L., Shelke, G. V., Hutchins, E., Hamamoto, A., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01004 · Cited by 551
Gupta, D., Zickler, A. M., & El Andaloussi, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113961 · Cited by 418
Kim, H. Y., Kim, T. J., Kang, L., Kim, Y.-J., Kang, M. K., Kim, J., Ryu, J. H., Hyeon, T., Yoon, B.-W., Ko, S.-B., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119942 · Cited by 321
Reis, M., Mavin, E., Nicholson, L., Green, K., Dickinson, A. M., & Wang, X.-N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02538 · Cited by 286
Metadata
- Authors
- Zhang, B., Yeo, R. W. Y., Lai, R. C., Sim, E. W. K., Chin, K. C., & Lim, S. K.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 20
- Issue
- 5
- Pages
- 687-696
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2796020748
- Cited by
- 208
- References
- 2
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cell exosome–enhanced regulatory T-cell production through an antigen-presenting cell–mediated pathway. https://app.cochat.ai/papers/10.1016/j.jcyt.2018.02.372
- The paper
- Zhang, B., Yeo, R. W. Y., Lai, R. C., Sim, E. W. K., Chin, K. C., & Lim, S. K. (2018). Mesenchymal stromal cell exosome–enhanced regulatory T-cell production through an antigen-presenting cell–mediated pathway. Cytotherapy. https://doi.org/10.1016/j.jcyt.2018.02.372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.